WSO - June 2023 - 535

Dalton et al.
535
Figure 1. A conceptualized model of the sampling process.
(Table 1). A criterion related to upper limb, cognition, language,
and contaminant condition were present in 70% or
more of the trials in the published data set and were also
included in the prospective data set (Table 1). An agerelated
criterion that restricted inclusion beyond adult (e.g.
age 20-80)16 was present in 50% of the published literature
but was not included in the prospective data set (Table 1).
Eligibility criteria filter (results)
An internal validity criterion was the primary exclusion
reason for 80.9% of patients from the published data set
(data available n = 6/30 trials) and 74.9% of patients from
the prospective data set. Internal validity criteria related to
upper-limb impairment (published: 20.4%, prospective:
45.9%) and no confirmed stroke (published: 15.4%, prospective:
22.9%) were the most common across both data
sets (Table 1). Primary and secondary exclusion reasons
were only available in the prospective data set; therefore,
the remaining eligibility criteria filter results are based on
the prospective data set only. Nearly 70% of patients were
excluded for more than one reason, with the combination of
internal validity and feasibility criteria most common
(n = 461, 45.8%), while a safety criterion alone was least
common (n = 7, 0.7%; Figure 2(a)).
The number of times individual criteria were implemented
as either a primary or secondary exclusion reason were captured
(Figure 2(b)). A SAFE score outside trial inclusion was
the most common exclusion criterion (n = 676), followed by
discharge outside of catchment (n = 293), discharge before
screening (n = 289, most before day 3), and no confirmed
stroke (n = 231). All but one exclusion criterion (palliation)
had a majority proportion of patients excluded for more than
just that criterion, as demonstrated by the stacked bar chart
(Figure 2(b)). The top-4 criteria accounted for nearly threequarters
(74.0%) of all exclusion reasons (Figure 2(b)).
To understand the impact of the top-4 criteria, the accessible
population with a confirmed stroke and reported
SAFE score (n = 669) were further examined. Scores were
grouped based on the SAFE eligibility criterion (too severe
SAFE 0-1; trial eligible SAFE 2-7; too good SAFE 8-10)
and patient characteristics described in Table 2. The majority
(84.2%) of patients fell outside the SAFE range (2-7),
with 38.1% of SAFE scores collected equalling 10. Just
under half (45.0%) received one or more acute stroke interventions
(Table 2). The median length of stay was 5 (3.0,
10.0) days. The length of stay for the too severe group was
over double (11 days) that of the too good group (4 days).
Patients
discharged
outside catchment
and
before
screening were the next two most prevalent exclusion reasons.
Figure 3 depicts the discharge location of the sample
grouped by SAFE score. Most of the too severe group
(42.6%) and trial-eligible group (39.6%) were discharged
to another acute hospital. These groups were often unable
to be recruited due to a length of stay shorter than the
required 8 days to complete the trial protocol.
International Journal of Stroke, 18(5)

WSO - June 2023

Table of Contents for the Digital Edition of WSO - June 2023

Contents
WSO - June 2023 - Cover1
WSO - June 2023 - Cover2
WSO - June 2023 - 491
WSO - June 2023 - Contents
WSO - June 2023 - 493
WSO - June 2023 - 494
WSO - June 2023 - 495
WSO - June 2023 - 496
WSO - June 2023 - 497
WSO - June 2023 - 498
WSO - June 2023 - 499
WSO - June 2023 - 500
WSO - June 2023 - 501
WSO - June 2023 - 502
WSO - June 2023 - 503
WSO - June 2023 - 504
WSO - June 2023 - 505
WSO - June 2023 - 506
WSO - June 2023 - 507
WSO - June 2023 - 508
WSO - June 2023 - 509
WSO - June 2023 - 510
WSO - June 2023 - 511
WSO - June 2023 - 512
WSO - June 2023 - 513
WSO - June 2023 - 514
WSO - June 2023 - 515
WSO - June 2023 - 516
WSO - June 2023 - 517
WSO - June 2023 - 518
WSO - June 2023 - 519
WSO - June 2023 - 520
WSO - June 2023 - 521
WSO - June 2023 - 522
WSO - June 2023 - 523
WSO - June 2023 - 524
WSO - June 2023 - 525
WSO - June 2023 - 526
WSO - June 2023 - 527
WSO - June 2023 - 528
WSO - June 2023 - 529
WSO - June 2023 - 530
WSO - June 2023 - 531
WSO - June 2023 - 532
WSO - June 2023 - 533
WSO - June 2023 - 534
WSO - June 2023 - 535
WSO - June 2023 - 536
WSO - June 2023 - 537
WSO - June 2023 - 538
WSO - June 2023 - 539
WSO - June 2023 - 540
WSO - June 2023 - 541
WSO - June 2023 - 542
WSO - June 2023 - 543
WSO - June 2023 - 544
WSO - June 2023 - 545
WSO - June 2023 - 546
WSO - June 2023 - 547
WSO - June 2023 - 548
WSO - June 2023 - 549
WSO - June 2023 - 550
WSO - June 2023 - 551
WSO - June 2023 - 552
WSO - June 2023 - 553
WSO - June 2023 - 554
WSO - June 2023 - 555
WSO - June 2023 - 556
WSO - June 2023 - 557
WSO - June 2023 - 558
WSO - June 2023 - 559
WSO - June 2023 - 560
WSO - June 2023 - 561
WSO - June 2023 - 562
WSO - June 2023 - 563
WSO - June 2023 - 564
WSO - June 2023 - 565
WSO - June 2023 - 566
WSO - June 2023 - 567
WSO - June 2023 - 568
WSO - June 2023 - 569
WSO - June 2023 - 570
WSO - June 2023 - 571
WSO - June 2023 - 572
WSO - June 2023 - 573
WSO - June 2023 - 574
WSO - June 2023 - 575
WSO - June 2023 - 576
WSO - June 2023 - 577
WSO - June 2023 - 578
WSO - June 2023 - 579
WSO - June 2023 - 580
WSO - June 2023 - 581
WSO - June 2023 - 582
WSO - June 2023 - 583
WSO - June 2023 - 584
WSO - June 2023 - 585
WSO - June 2023 - 586
WSO - June 2023 - 587
WSO - June 2023 - 588
WSO - June 2023 - 589
WSO - June 2023 - 590
WSO - June 2023 - 591
WSO - June 2023 - 592
WSO - June 2023 - 593
WSO - June 2023 - 594
WSO - June 2023 - 595
WSO - June 2023 - 596
WSO - June 2023 - 597
WSO - June 2023 - 598
WSO - June 2023 - 599
WSO - June 2023 - 600
WSO - June 2023 - 601
WSO - June 2023 - 602
WSO - June 2023 - 603
WSO - June 2023 - 604
WSO - June 2023 - 605
WSO - June 2023 - 606
WSO - June 2023 - 607
WSO - June 2023 - 608
WSO - June 2023 - 609
WSO - June 2023 - 610
WSO - June 2023 - 611
WSO - June 2023 - 612
WSO - June 2023 - 613
WSO - June 2023 - 614
WSO - June 2023 - 615
WSO - June 2023 - 616
WSO - June 2023 - 617
WSO - June 2023 - 618
WSO - June 2023 - 619
WSO - June 2023 - 620
WSO - June 2023 - 621
WSO - June 2023 - 622
WSO - June 2023 - 623
WSO - June 2023 - 624
WSO - June 2023 - 625
WSO - June 2023 - 626
WSO - June 2023 - Cover3
WSO - June 2023 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com